Abbott Receives FDA Authorization for Libre Duo 10 Day: World’s First Dual Continuous Glucose and Ketone Monitoring System for Early DKA Warning

September 20, 2026

Medical Update Online (Abbott) USA

Overview

Abbott has secured FDA authorization for its Libre Duo 10 Day, the world’s first dual continuous glucose and ketone monitoring (CGKM) system. This novel bio-wearable provides real-time glucose levels while continuously monitoring for elevated ketones, offering early warnings for diabetic ketoacidosis (DKA) in diabetic patients. The system aims to significantly enhance diabetes management and prevent acute emergencies, with a planned US launch later this year.

In Depth

Key Findings

Abbott announced it has received US FDA authorization for the Libre Duo 10 Day, the world’s first dual continuous glucose and ketone monitoring (CGKM) system for people with diabetes. This groundbreaking wearable biosensor provides real-time glucose readings alongside continuous ketone monitoring, designed to offer early warnings for rising ketone levels that can lead to diabetic ketoacidosis (DKA), a life-threatening emergency.

Technical / Clinical Details

The Libre Duo 10 Day system is engineered as a wearable sensor that continuously tracks both glucose and ketone levels in interstitial fluid. This integrated approach allows patients to obtain a more comprehensive understanding of their metabolic status beyond just glucose, significantly reducing the need for frequent finger-prick blood glucose tests. For insulin-dependent individuals, monitoring ketones is crucial as elevated levels are a primary indicator of impending DKA. The system is programmed to alert patients and their linked healthcare providers when ketone levels approach dangerous thresholds, facilitating timely intervention and potentially averting severe complications.

Background & Context

Continuous Glucose Monitoring (CGM) has revolutionized diabetes care by improving quality of life and management for millions. However, a gap remained in continuous, integrated ketone monitoring, particularly for high-risk patients prone to DKA. The FDA’s authorization of Libre Duo 10 Day marks a significant leap, establishing a new standard in proactive diabetes management. DKA is a serious complication characterized by excessive ketone body production due to insulin deficiency, demanding rapid medical attention.

Strategic Significance & Outlook

Abbott plans to launch the Libre Duo 10 Day in the US market within the year. The introduction of this innovative technology is expected to substantially lower DKA incidence and elevate the quality of life for diabetes patients. It will also spearhead the creation and expansion of a continuous ketone monitoring market, paving the way for future integrated biosensor developments. Healthcare providers will gain access to a richer dataset encompassing both glucose and ketone trends, enabling more personalized and effective treatment strategies.

Source: https://medicalupdateonline.com/2026/09/fda-authorizes-libre-duo-10-day-worlds-first-dual-continuous-glucose-ketone-monitoring-system-for-people-with-diabetes-abbott/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.